3,975 Shares in Gilead Sciences, Inc. $GILD Acquired by Western Wealth Management LLC

Western Wealth Management LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ:GILD) during the second quarter, Holdings Channel.com reports. The fund bought 3,975 shares of the biopharmaceutical company’s stock, valued at approximately $502,000.

Several other hedge funds have also bought and sold shares of the stock. Strategic Investment Solutions Inc. IL bought a new position in shares of Gilead Sciences in the 4th quarter worth $25,000. Persistent Asset Partners Ltd bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $25,000. Vermillion & White Wealth Management Group LLC grew its position in Gilead Sciences by 71.4% in the fourth quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 85 shares in the last quarter. Quattro Advisors LLC purchased a new position in Gilead Sciences in the fourth quarter worth $26,000. Finally, Wealth Preservation Advisors LLC increased its stake in Gilead Sciences by 60.0% in the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 81 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Stock Performance

NASDAQ GILD opened at $148.77 on Wednesday. The company has a 50-day simple moving average of $132.85 and a two-hundred day simple moving average of $136.59. The company has a quick ratio of 1.09, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12-month low of $108.46 and a 12-month high of $157.29. The firm has a market cap of $184.47 billion, a price-to-earnings ratio of -55.72 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping the consensus estimate of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter in the previous year, the business earned $2.01 earnings per share. The company’s quarterly revenue was up 10.6% on a year-over-year basis. On average, equities analysts forecast that Gilead Sciences, Inc. will post -0.5 EPS for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s payout ratio is -122.85%.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the company. Wall Street Zen upgraded Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Saturday, August 15th. Rothschild & Co Redburn reduced their price objective on Gilead Sciences from $170.00 to $167.00 in a research report on Monday, May 11th. Morgan Stanley decreased their price objective on Gilead Sciences from $166.00 to $165.00 and set an “overweight” rating on the stock in a report on Monday, July 27th. Royal Bank Of Canada boosted their target price on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research report on Wednesday, August 5th. Finally, Weiss Ratings lowered Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Twenty-four research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $158.04.

Insider Buying and Selling

In other news, CEO Daniel Patrick O’day sold 15,000 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the sale, the chief executive officer owned 592,133 shares of the company’s stock, valued at approximately $77,160,851.23. This represents a 2.47% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Jeffrey Bluestone sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the completion of the transaction, the director owned 10,066 shares in the company, valued at $1,459,771.32. This represents a 33.19% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 87,000 shares of company stock valued at $11,562,960 over the last quarter. Company insiders own 0.30% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.